Source:http://linkedlifedata.com/resource/pubmed/id/10942162
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2000-12-12
|
pubmed:abstractText |
The haemodynamic hypothesis for the pathogenesis of diabetic microangiopathy argues that an initial increase in microvascular blood flow leads to microvascular sclerosis and disturbed autoregulation. Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide that contributes to basal vascular tone. Impairment of the vasoconstrictor response to ET-1 could result in hyperperfusion and subsequent microvascular damage. The purpose of this study was to determine whether vascular responses to ET-1 are impaired in patients with non-insulin-dependent diabetes mellitus (type 2 diabetes). Ten patients with type 2 diabetes and nine control subjects underwent brachial artery cannulation. Forearm blood flow was measured using strain-gauge venous occlusion plethysmography. ET-1 in three doses of 5, 10, and 20 pmol/min and 0.9% saline placebo was infused in a balanced double-blind randomised manner. Vascular smooth muscle function also was assessed using sodium nitroprusside. Control subjects showed vasoconstriction to ET-1 of 5 (p < 0.05), 10 (p < 0.05), and 20 pmol/min (p < 0.01). In the diabetic group, there was no significant response to ET-1 at 5 pmol/min (p > 0.05); however, significant vasoconstriction developed at 10 and 20 pmol/min (p < 0.01). There was a significant difference in response to ET-1 at 5 pmol/min between the diabetic and control groups (p < 0.05). Responses to sodium nitroprusside were similar in both groups (p > 0.05). Patients with type 2 diabetes have a blunted vasoconstrictor response to ET-1 despite preserved vascular smooth muscle function.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0160-2446
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
203-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10942162-Adult,
pubmed-meshheading:10942162-Aged,
pubmed-meshheading:10942162-Area Under Curve,
pubmed-meshheading:10942162-Blood Glucose,
pubmed-meshheading:10942162-Diabetes Mellitus, Type 2,
pubmed-meshheading:10942162-Dose-Response Relationship, Drug,
pubmed-meshheading:10942162-Double-Blind Method,
pubmed-meshheading:10942162-Endothelin-1,
pubmed-meshheading:10942162-Female,
pubmed-meshheading:10942162-Forearm,
pubmed-meshheading:10942162-Humans,
pubmed-meshheading:10942162-Male,
pubmed-meshheading:10942162-Middle Aged,
pubmed-meshheading:10942162-Regional Blood Flow,
pubmed-meshheading:10942162-Vasoconstriction
|
pubmed:year |
2000
|
pubmed:articleTitle |
Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: a dose-response study.
|
pubmed:affiliation |
Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Northern Ireland. dan.mcauley@dtn.ntl.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|